Author:
Pandey Sneha,Tiwari Syona,Basu Sulagna,Mishra Rajiv Kumar,Pandey Rakesh
Abstract
The pathogenesis of the inflammatory, chronic, and common skin disease psoriasis involves immune cells, skin cells (keratinocytes), and the cytokines they secrete. Hyperproliferation and abnormal differentiation of keratinocytes are hallmarks of the disease. The roles of cytokines such as TNFα, IL-15, IL-17, and IL-23 in psoriasis have been studied through mathematical/computational models as well as experiments. However, the role of proinflammatory cytokine IL-36 in the onset and progression of psoriasis is still elusive. To explore the role of IL-36, we construct a network embodying indirect cell–cell interactions of a few immune and skin cells mediated by IL-36 based on existing knowledge. We also develop a mathematical model for the network and perform a global sensitivity analysis. Our results suggest that the model is most sensitive to a parameter that represents the level of cytokine IL-36. In addition, a steady-state analysis of the model suggests that an increase in the level of IL-36 could lead to the hyperproliferation of keratinocytes and, thus, psoriasis. Our analysis also highlights that the plaque formation and progression of psoriasis could occur through either a gradual or a switch-like increase in the keratinocyte population. We propose that the switch-like increase would be due to a bistable behavior of the network toward either a psoriatic or healthy state and could be used as a novel treatment strategy.
Reference39 articles.
1. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis;Bachelez;N. Engl. J. Med.,2019
2. IL-36γ is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis;Bridgewood;Front. Immunol.,2018
3. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis;Carrier;J. Investigative Dermatology,2011
4. Correlation analysis between IL-35, IL-36 γ, CCL27 and psoriasis vulgaris;Chen;J. Dermatological Treat.,2021
5. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare;Choon;BMJ open.